#United States #Dublin #Perrigo #Abbie Lennox #Chief Scientific Office

Perrigo Expands Its Scientific Office

In a recent announcement, Perrigo Company plc (NYSE: PRGO), a prominent global supplier of Consumer Self-Care Products, unveiled its strategic expansion of the Chief Scientific Office. This development aims to consolidate various scientific operations, including global quality, pharmacovigilance, patient safety, regulatory affairs, and innovation teams, into a single cohesive unit. The integration is designed to boost organizational agility and enhance efficiencies within the company's pipeline of consumer-led innovations.

To steer this newly structured office, Perrigo appointed Abbie Lennox as Executive Vice President and Chief Scientific Officer. Ms. Lennox brings a wealth of experience from her previous role at Bayer, where she significantly advanced regulatory standards and spearheaded various product innovations within their consumer health division.

President and CEO Patrick Lockwood-Taylor expressed confidence in this new direction, stating, "Bringing quality, regulatory, and innovation efforts under one umbrella is vital for our evolution and vision to create One Perrigo. Abbie has the right expertise to lead this effort and to champion consumer-focused innovation that meets our high standards."

Ms. Lennox's past achievements underscore her qualifications for this leadership role. At Bayer, she was instrumental in overseeing regulatory, medical affairs, safety, and quality functions. Her endeavors included the successful launch of numerous products and initiatives across several global categories, such as allergy treatments, digestive health, and various wellness products. Notably, she played a crucial role in the U.S. Rx-to-OTC switch for Astepro®, advocating for consumer-oriented claims backed by strong clinical data. Furthermore, Ms. Lennox pioneered the launch of Rennie® Gum, the first OST chewing gum for digestive health in Europe, carefully navigating clinical and registration challenges while emphasizing consumer experience.

Before her tenure at Bayer, Ms. Lennox honed her skills in regulatory affairs at Reckitt Benckiser, enhancing their approach to delivering products across a diverse portfolio of health brands. She holds a First Class BSc (Honors) in Biomedical Science and Chemistry from De Montfort University, providing her with a solid educational foundation for her work in the consumer health realm.

Upon her appointment, Lennox shared her enthusiasm for joining Perrigo at such a pivotal moment. "I am excited to contribute to Perrigo's legacy in providing exceptional self-care products that adhere to high-quality standards. I look forward to collaborating with my colleagues to elevate Perrigo's innovation pipeline and to lead the charge in the self-care industry."

The previous Chief Scientific Officer, Alison Ives, has been tasked with leading a newly formed Disruptive Growth Team. This team's mission will focus on uncovering and pursuing emerging opportunities within category disruption and entering new markets. Ms. Ives’s extensive experience in scientific roles for over two decades positions her well to unlock growth potential within the company.

About Perrigo

Perrigo Company plc is recognized as a leader in Consumer Self-Care Products and OTC health solutions, designed to enhance individual well-being by empowering consumers to prevent or manage their health conditions independently. For more information on Perrigo and its innovative solutions, visit Perrigo’s official website.

Conclusion

With the strategic expansion of its Chief Scientific Office and the leadership of Abbie Lennox, Perrigo is well-positioned to drive innovation and maintain its commitment to consumer health. As the company continues to adapt and evolve in a competitive market, its focus on quality and collaboration will undoubtedly contribute to future success.